Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine

Enterovirus 71 (EV71) is a neurotropic human pathogen that is the causative agent of hand foot and mouth disease (HFMD), herpangina and brain stem encephalitis. Recurrent EV71 epidemics of various scales have occurred in the Asia-Pacific region. Several specific cell surface molecules serve as the receptors for EV71. Identification of the receptors is an important step to understand EV71 disease. Cytokines, lymphocytes and monocytes contribute significantly to EV71 pathogenesis. The interaction of EV71 and receptors may be associated with the cytokines immunopathogenesis. Some animal models have been established and aim to explore the pathogenesis of EV71 infections. EV71 antibodies can neutralize or enhance infection at subneutralizing levels. These results are important for EV71 vaccine and therapeutics design. Several clinical trials of human inactivated EV71 vaccine have recently been completed. The purpose of this review is to summarize recent discoveries about the epidemiology and pathogenesis of EV71 and provide insights into human vaccine development.

[1]  Shixia Wang,et al.  EV71: an emerging infectious disease vaccine target in the Far East? , 2010, Vaccine.

[2]  P. McMinn.  The emergence of enterovirus 71 as a major cause of acute neurological disease in young children of the Asia-Pacific region , 2006, Journal of Pediatric Infectious Diseases.

[3]  Hongling Zhao,et al.  Pathogenesis study of enterovirus 71 infection in rhesus monkeys , 2011, Laboratory Investigation.

[4]  E. H. Lennette,et al.  An apparently new enterovirus isolated from patients with disease of the central nervous system. , 1974, The Journal of infectious diseases.

[5]  Wenfei Zhu,et al.  Excessive proinflammatory cytokine and chemokine responses of human monocyte-derived macrophages to enterovirus 71 infection , 2012, BMC Infectious Diseases.

[6]  Ching-Chuan Liu,et al.  Enterovirus 71: epidemiology, pathogenesis and management , 2009, Expert review of anti-infective therapy.

[7]  H. Lei,et al.  Cytokine Immunopathogenesis of Enterovirus 71 Brain Stem Encephalitis , 2012, Clinical and Developmental Immunology.

[8]  B. Böttiger,et al.  Clinical and virological features of enterovirus 71 infections in Denmark, 2005 to 2008 , 2011, Scandinavian journal of infectious diseases.

[9]  F. Zhu,et al.  Immunogenicity, Safety, and Lot Consistency of a Novel Inactivated Enterovirus 71 Vaccine in Chinese Children Aged 6 to 59 Months , 2013, Clinical and Vaccine Immunology.

[10]  Sheng-Wen Huang,et al.  Reemergence of Enterovirus 71 in 2008 in Taiwan: Dynamics of Genetic and Antigenic Evolution from 1998 to 2008 , 2009, Journal of Clinical Microbiology.

[11]  P. Phuektes,et al.  Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. , 2011, Vaccine.

[12]  Jen-Ren Wang,et al.  Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. , 2003, The Journal of infectious diseases.

[13]  C. Partidos,et al.  Adaptation of Enterovirus 71 to Adult Interferon Deficient Mice , 2013, PloS one.

[14]  H. Pan,et al.  Patterns of polymorphism and divergence in the VP1 gene of enterovirus 71 circulating in the Asia-Pacific region between 1994 and 2013. , 2013, Journal of virological methods.

[15]  I. Sam,et al.  Enterovirus 71 Outbreak, Brunei , 2009, Emerging infectious diseases.

[16]  Pei Liu,et al.  Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2013, The Lancet.

[17]  T. Yeh,et al.  Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  T. Tsang,et al.  Estimation of the Basic Reproduction Number of Enterovirus 71 and Coxsackievirus A16 in Hand, Foot, and Mouth Disease Outbreaks , 2011, The Pediatric infectious disease journal.

[19]  Jen-Ren Wang,et al.  Therapeutic efficacy of milrinone in the management of enterovirus 71‐induced pulmonary edema , 2005, Pediatric pulmonology.

[20]  Y. Chow,et al.  Caveolar Endocytosis Is Required for Human PSGL-1-Mediated Enterovirus 71 Infection , 2013, Journal of Virology.

[21]  Yongqiang Deng,et al.  Antibody dependent enhancement infection of Enterovirus 71 in vitro and in vivo , 2011, Virology Journal.

[22]  N. Xia,et al.  The Cross-Neutralizing Activity of Enterovirus 71 Subgenotype C4 Vaccines in Healthy Chinese Infants and Children , 2013, PloS one.

[23]  T. Wakita,et al.  Tyrosine Sulfation of the Amino Terminus of PSGL-1 Is Critical for Enterovirus 71 Infection , 2010, PLoS pathogens.

[24]  H. Lei,et al.  A murine oral enterovirus 71 infection model with central nervous system involvement. , 2004, The Journal of general virology.

[25]  Szu-Wei Huang,et al.  Molecular Epidemiology of Enterovirus 71 Infection in the Central Region of Taiwan from 2002 to 2012 , 2013, PloS one.

[26]  Shainn-Wei Wang,et al.  Enterovirus 71 Infection of Human Dendritic Cells , 2009, Experimental biology and medicine.

[27]  M. Ho,et al.  Annexin II Binds to Capsid Protein VP1 of Enterovirus 71 and Enhances Viral Infectivity , 2011, Journal of Virology.

[28]  Feng Ruan,et al.  Risk Factors for Hand, Foot, and Mouth Disease and Herpangina and the Preventive Effect of Hand-washing , 2011, Pediatrics.

[29]  Mei-Chih Huang,et al.  Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[30]  Y. Kawaoka,et al.  Antibody‐dependent enhancement of viral infection: molecular mechanisms and in vivo implications , 2003, Reviews in medical virology.

[31]  Jen-Ren Wang,et al.  Cell surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and neuroblastoma cells , 2012, BMC Microbiology.

[32]  L. Wahl,et al.  Perspectives on the basic reproductive ratio , 2005, Journal of The Royal Society Interface.

[33]  Jen-Ren Wang,et al.  Genetic and Antigenic Characterization of Enterovirus 71 in Ho Chi Minh City, Vietnam, 2011 , 2013, PloS one.

[34]  Jia Jun Lee,et al.  A Non-Mouse-Adapted Enterovirus 71 (EV71) Strain Exhibits Neurotropism, Causing Neurological Manifestations in a Novel Mouse Model of EV71 Infection , 2011, Journal of Virology.

[35]  SB Halstead,et al.  Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody , 1977, The Journal of experimental medicine.

[36]  Ho‐Sheng Wu,et al.  Antigenic and Genetic Diversity of Human Enterovirus 71 from 2009 to 2012, Taiwan , 2013, PloS one.

[37]  Shun-Hua Chen,et al.  Lymphocyte and Antibody Responses Reduce Enterovirus 71 Lethality in Mice by Decreasing Tissue Viral Loads , 2009, Journal of Virology.

[38]  Xing Wu,et al.  Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial , 2013, The Lancet.

[39]  W. Ryu,et al.  Enterovirus 71 Infection with Central Nervous System Involvement, South Korea , 2010, Emerging infectious diseases.

[40]  D. Dimitrov,et al.  Virus entry: molecular mechanisms and biomedical applications , 2004, Nature Reviews Microbiology.

[41]  S. Koike,et al.  Scavenger receptor B2 is a cellular receptor for enterovirus 71 , 2009, Nature Medicine.

[42]  P. Chong,et al.  Protective Efficacy of VP1-Specific Neutralizing Antibody Associated with a Reduction of Viral Load and Pro-Inflammatory Cytokines in Human SCARB2-Transgenic Mice , 2013, PloS one.

[43]  K. Tsao,et al.  An Investigation of Epidemic Enterovirus 71 Infection in Taiwan, 2008: Clinical, Virologic, and Serologic Features , 2010, The Pediatric infectious disease journal.

[44]  K. Fujii,et al.  Transgenic mouse model for the study of enterovirus 71 neuropathogenesis , 2013, Proceedings of the National Academy of Sciences.

[45]  H. Lei,et al.  Enterovirus 71 Infection of Monocytes with Antibody-Dependent Enhancement , 2010, Clinical and Vaccine Immunology.

[46]  K. Wong,et al.  Formaldehyde-Inactivated Whole-Virus Vaccine Protects a Murine Model of Enterovirus 71 Encephalomyelitis against Disease , 2009, Journal of Virology.

[47]  I. Sam,et al.  Enterovirus 71 Uses Cell Surface Heparan Sulfate Glycosaminoglycan as an Attachment Receptor , 2012, Journal of Virology.

[48]  P. Chong,et al.  Human SCARB2 Transgenic Mice as an Infectious Animal Model for Enterovirus 71 , 2013, PloS one.

[49]  C. Qin,et al.  Characterization of enterovirus 71 and coxsackievirus A16 isolated in hand, foot, and mouth disease patients in Guangdong, 2010. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[50]  Hyunwook Lee,et al.  Enterovirus 71 Binding to PSGL-1 on Leukocytes: VP1-145 Acts as a Molecular Switch to Control Receptor Interaction , 2013, PLoS pathogens.

[51]  Yhu-Chering Huang,et al.  Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  Rong-cheng Li,et al.  Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. , 2012, Vaccine.

[53]  A. Nomoto,et al.  Receptor-Dependent and -Independent Axonal Retrograde Transport of Poliovirus in Motor Neurons , 2009, Journal of Virology.

[54]  Yufen Xu,et al.  Proteomic analysis of extremely severe hand, foot and mouth disease infected by enterovirus 71 , 2013, BMC Infectious Diseases.

[55]  Wenbo Xu,et al.  The Persistent Circulation of Enterovirus 71 in People's Republic of China: Causing Emerging Nationwide Epidemics Since 2008 , 2011, PloS one.

[56]  M. Phoon,et al.  The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[57]  Mei-Chih Huang,et al.  Long-term Cognitive and Motor Deficits After Enterovirus 71 Brainstem Encephalitis in Children , 2006, Pediatrics.

[58]  Tom Solomon,et al.  Virology, epidemiology, pathogenesis, and control of enterovirus 71. , 2010, The Lancet. Infectious diseases.

[59]  Huaxi Xu,et al.  Increased frequency of Th17 cells in the peripheral blood of children infected with enterovirus 71 , 2012, Journal of medical virology.

[60]  Wenbo Xu,et al.  Emergence and Transmission Pathways of Rapidly Evolving Evolutionary Branch C4a Strains of Human Enterovirus 71 in the Central Plain of China , 2011, PloS one.

[61]  M. Pallansch,et al.  Molecular Epidemiology and Evolution of Enterovirus 71 Strains Isolated from 1970 to 1998 , 1999, Journal of Virology.

[62]  N. Zhao,et al.  Association of interleukin 10 and interferon gamma gene polymorphisms with enterovirus 71 encephalitis in patients with hand, foot and mouth disease , 2012, Scandinavian journal of infectious diseases.

[63]  J. Deshpande,et al.  Enterovirus 71 isolated from a case of acute flaccid paralysis in India represents a new genotype , 2003 .

[64]  Zhenglun Liang,et al.  Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial. , 2014, The Journal of infectious diseases.

[65]  P. Simmonds,et al.  The Association of Recombination Events in the Founding and Emergence of Subgenogroup Evolutionary Lineages of Human Enterovirus 71 , 2011, Journal of Virology.

[66]  H. Lei,et al.  Exogenous interleukin-6, interleukin-13, and interferon-gamma provoke pulmonary abnormality with mild edema in enterovirus 71-infected mice , 2011, Respiratory research.

[67]  S. Trasti,et al.  Sustained High Levels of Interleukin-6 Contribute to the Pathogenesis of Enterovirus 71 in a Neonate Mouse Model , 2011, Journal of Virology.

[68]  B. Lina,et al.  Epidemiology of human enterovirus 71 infections in France, 2000-2009. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[69]  Ya-Fang Wang,et al.  Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. , 2011, Vaccine.

[70]  Kow-Tong Chen,et al.  The Association between Enterovirus 71 Infections and Meteorological Parameters in Taiwan , 2012, PloS one.

[71]  Kow-Tong Chen,et al.  Epidemiologic Features of Hand-Foot-Mouth Disease and Herpangina Caused by Enterovirus 71 in Taiwan, 1998–2005 , 2007, Pediatrics.

[72]  Jen-Ren Wang,et al.  Formalin-Inactivated EV71 Vaccine Candidate Induced Cross-Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers , 2013, PloS one.

[73]  K. Fujii,et al.  Functional Comparison of SCARB2 and PSGL1 as Receptors for Enterovirus 71 , 2013, Journal of Virology.

[74]  T. Solomon,et al.  Clinical features, diagnosis, and management of enterovirus 71 , 2010, The Lancet Neurology.

[75]  K. Chu,et al.  Reactogenicity and Immunogenicity of an Enterovirus 71 Vaccine in Chinese Healthy Children and Infants , 2012, The Pediatric infectious disease journal.

[76]  Min-Shi Lee,et al.  Development of enterovirus 71 vaccines , 2010, Expert review of vaccines.

[77]  Jen-Ren Wang,et al.  Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. , 2008, The Journal of infectious diseases.

[78]  M. Koopmans,et al.  Epidemiology of Enterovirus 71 in The Netherlands, 1963 to 2008 , 2009, Journal of Clinical Microbiology.

[79]  S. Dowell,et al.  What we are watching—five top global infectious disease threats, 2012: a perspective from CDC’s Global Disease Detection Operations Center , 2013, Emerging health threats journal.

[80]  I. Su,et al.  Enterovirus 71 infection increases expression of interferon-gamma-inducible protein 10 which protects mice by reducing viral burden in multiple tissues. , 2013, The Journal of general virology.

[81]  M. Shimojima,et al.  Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71 , 2009, Nature Medicine.

[82]  S. Self,et al.  Implications of Age-Dependent Immune Responses to Enterovirus 71 Infection for Disease Pathogenesis and Vaccine Design. , 2013, Journal of the Pediatric Infectious Diseases Society.

[83]  Da-yong Dong,et al.  Human IgG Subclasses against Enterovirus Type 71: Neutralization versus Antibody Dependent Enhancement of Infection , 2013, PloS one.

[84]  H. Lei,et al.  Reemerging of enterovirus 71 in Taiwan: the age impact on disease severity , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[85]  K. Fujii,et al.  Human SCARB2-Dependent Infection by Coxsackievirus A7, A14, and A16 and Enterovirus 71 , 2012, Journal of Virology.

[86]  T. Solomon,et al.  In enterovirus 71 encephalitis with cardio-respiratory compromise, elevated interleukin 1β, interleukin 1 receptor antagonist, and granulocyte colony-stimulating factor levels are markers of poor prognosis. , 2012, The Journal of infectious diseases.